Evidence map›Paper›PMID 26296643›Full record

ArticleJournal of the National Cancer Institute2015

Gender Disparity and Mutation Burden in Metastatic Melanoma.

Sameer Gupta, Mykyta Artomov, William Goggins, Mark Daly, Hensin Tsao

Open access · greenAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Journal of the National Cancer Institute, 2015. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 78 papers, 5 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
78citing papers in PubMed, 5 pooled it
2.9field-weighted citation impact, top 8% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

78 citing papers in PubMed, 5 syntheses or guidelines pooled it, 150 citations in OpenAlex.

  1. Pooled it
  2. Pooled it
  3. Pooled it
  4. Pooled it
  5. Pooled it
  6. Trial
  7. Trial
  8. Trial
  9. Article
  10. Article
  11. Article
  12. Review
  13. Life Factors and Melanoma: From the Macroscopic State to the Molecular Mechanism.Advanced science (Weinheim, Baden-Wurttemberg, Germany) · 2025
    Review
  14. Review
  15. Article
  16. Article
  17. Article
  18. Article
  19. Article
  20. Article

18 more citing papers are in PubMed but not listed here.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

5 authors at 4 institutions in 1 country.

Sameer GuptaWellman Center for Photomedicine, Department of Dermatology, Massachusetts General Hospital, Harvard Medical School, Boston, MA (SG, HT); Analytic and Translational Genetic Unit, Massachusetts General Hospital, Boston, MA (MA, MD); Broad Institute, Cambridge, MA (MA, MD); Chemistry and Chemical Biology Department, Harvard University, Cambridge, MA (MA); School of Public Health and Primary Care, The Chinese University of Hong Kong, Hong Kong (WG).
Mykyta ArtomovWellman Center for Photomedicine, Department of Dermatology, Massachusetts General Hospital, Harvard Medical School, Boston, MA (SG, HT); Analytic and Translational Genetic Unit, Massachusetts General Hospital, Boston, MA (MA, MD); Broad Institute, Cambridge, MA (MA, MD); Chemistry and Chemical Biology Department, Harvard University, Cambridge, MA (MA); School of Public Health and Primary Care, The Chinese University of Hong Kong, Hong Kong (WG).
William GogginsWellman Center for Photomedicine, Department of Dermatology, Massachusetts General Hospital, Harvard Medical School, Boston, MA (SG, HT); Analytic and Translational Genetic Unit, Massachusetts General Hospital, Boston, MA (MA, MD); Broad Institute, Cambridge, MA (MA, MD); Chemistry and Chemical Biology Department, Harvard University, Cambridge, MA (MA); School of Public Health and Primary Care, The Chinese University of Hong Kong, Hong Kong (WG).
Mark DalyWellman Center for Photomedicine, Department of Dermatology, Massachusetts General Hospital, Harvard Medical School, Boston, MA (SG, HT); Analytic and Translational Genetic Unit, Massachusetts General Hospital, Boston, MA (MA, MD); Broad Institute, Cambridge, MA (MA, MD); Chemistry and Chemical Biology Department, Harvard University, Cambridge, MA (MA); School of Public Health and Primary Care, The Chinese University of Hong Kong, Hong Kong (WG).
Hensin TsaoWellman Center for Photomedicine, Department of Dermatology, Massachusetts General Hospital, Harvard Medical School, Boston, MA (SG, HT); Analytic and Translational Genetic Unit, Massachusetts General Hospital, Boston, MA (MA, MD); Broad Institute, Cambridge, MA (MA, MD); Chemistry and Chemical Biology Department, Harvard University, Cambridge, MA (MA); School of Public Health and Primary Care, The Chinese University of Hong Kong, Hong Kong (WG). htsao@partners.org.
Broad Institute · USHarvard University · USHarvard University Press · USMassachusetts General Hospital · US

Funding

Molecular Risk Assessment in Hereditary MelanomaK24CA149202 · NCI · MASSACHUSETTS GENERAL HOSPITAL · PI TSAO, HENSIN · 2010 to 2019
$1.9M
NCI NIH HHS K24 CA149202
6 · The paper itself

Abstract

Gender differences in melanoma incidence and outcome have been consistently observed but remain biologically unexplained. We hypothesized that tumors are genetically distinct between men and women and analyzed the mutation spectra in 266 metastatic melanomas (102 women and 164 men) from The Cancer Genome Atlas (TCGA). We found a statistically significantly greater burden of missense mutations among men (male median 298 vs female median = 211.5; male-to-female ratio [M:F] = 1.85, 95% confidence interval [CI] = 1.44 to 2.39). We validated these initial findings using available data from a separate melanoma exome cohort (n = 95) and found a similar increase in missense mutations among men (male median 393 vs female median 259; M:F = 1.59, 95% CI = 1.12 to 2.27). In addition, we found improved survival with increasing log-transformed missense mutation count (univariate hazard ratio = 0.82, 95% CI = 0.69 to 0.98) for TCGA samples. Our analyses demonstrate for the first time a gender difference in mutation burden in cutaneous melanoma.

Indexed as

Mutation, MissenseAdultAgedCutaneous Malignant MelanomaExomeFemaleGTP PhosphohydrolasesHumansIncidenceMaleMelanomaMembrane ProteinsMiddle AgedOdds RatioProto-Oncogene Proteins B-rafReproducibility of ResultsBRAF protein, humanGTP PhosphohydrolasesMembrane ProteinsNRAS protein, humanProto-Oncogene Proteins B-raf

Identifiers

PMID26296643
PMCPMC4643631
OpenAlexW1679888031

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.